In this review, we discuss the significance of targeting DNA damage repair pathways in prostate cancer and focus in particular on covering the biological background and clinical potential of drugs inhibiting Poly(ADP-ribose) polymerase (PARP) enzymes which are also uniquely connected to AR signaling. Here, PARP1 is linked to prostate cancer.